| Project/Area Number |
26462401
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Takeshima Yuta 東京大学, 医学部附属病院, 登録診療員 (10372393)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
福原 浩 東京大学, 医学部附属病院, 准教授 (20292948)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | 遺伝子治療 / ウイルス療法 / ヘルペスウイルスＩ型 / 泌尿器がん / HSV-1 / 前立腺がん / 腎がん / 前立腺癌 / 腎癌 |
|---|
| Outline of Final Research Achievements |
The triple-deleted oncolytic herpes simplex virus type I G47delta represents the cutting edge of a new field of oncotherapy utilizing genetically-engineered viruses. Of the three deletions, the deletion of the ICP6 gene may in theory make viral replication reliant on host enzyme level, and thus be inhibited in slower-growing tumors. Using the G47delta as the backbone, we created a new oncolytic HSV-1 with an intact ICP6 gene under the control of tumor-specific promoters to eliminate this effect, and enhance viral growth and efficacy against slower-growing tumors. We hope this new virus will further stimulate the use of viral agents in oncotherapy.
|
